Rabies virus inactivated antigen, A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Rabies virus inactivated antigen, A
Accession Number
DB10283
Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Description

Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.

Synonyms
  • Rabies virus strain flury lep antigen (propiolactone inactivated)
  • Rabies virus vaccine flury-lep strain
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
RabAvertKit2.5 [iU]/1mLGSK Vaccines GmbH2014-07-082020-03-31Us
RabAvertKit2.5 [iU]/1mLGlaxoSmithKline Biologicals SA2016-12-19Not applicableUs
RabAvertKit2.5 [iU]/1mLA-S Medication Solutions2014-07-082020-03-31Us
RabAvertKit2.5 [iU]/1mLA-S Medication Solutions2016-12-19Not applicableUs
Categories
UNII
FK894Q51YE
CAS number
Not Available

Pharmacology

Indication
Not Available
Associated Conditions
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2-MethoxyethanolThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with 2-Methoxyethanol.
6-Deoxyerythronolide BThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with 6-Deoxyerythronolide B.
9-(N-methyl-L-isoleucine)-cyclosporin AThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with 9-(N-methyl-L-isoleucine)-cyclosporin A.
AbataceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abatacept.
AbetimusThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abetimus.
Acetyl sulfisoxazoleThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Acetyl sulfisoxazole.
ActeosideThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Acteoside.
AdalimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adalimumab.
AfelimomabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Afelimomab.
AldesleukinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Aldesleukin.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347910469
ATC Codes
J06AA06 — Rabies serum

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedPreventionPlasmodium Falciparum Malaria1
1CompletedPreventionPlasmodium Falciparum Malaria / Plasmodium Infections1
1RecruitingPreventionMalaria caused by Plasmodium falciparum1
1Unknown StatusPreventionPlasmodium Infections1
1, 2CompletedPreventionPlasmodium Infections1
2Active Not RecruitingPreventionPlasmodium Infections1
2CompletedPreventionPlasmodium Falciparum Malaria1
2CompletedPreventionPlasmodium Infections2
2CompletedPreventionRabies1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Unknown StatusPreventionRabies Pre-exposure Prophylaxis1
3CompletedPreventionEncephalitis, Japanese B / Meningococcal Disease / Meningococcal Meningitis / Rabies / Salmonella Typhi Infection / Yellow Fever1
3CompletedPreventionRabies Infection1
3CompletedPreventionRabies Post-exposure Prophylaxis1
3CompletedPreventionRabies Prevention1
4CompletedNot AvailableRabies1
4CompletedPreventionRabies1
4CompletedPreventionRabies Vaccine Allergy1
4RecruitingBasic ScienceRabies Human1
4RecruitingPreventionRabies1
Not AvailableCompletedPreventionRabies1
Not AvailableCompletedPreventionRabies Exposure / Rabies Prevention1
Not AvailableRecruitingTreatmentRabies1
Not AvailableUnknown StatusNot AvailableDog Bite1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Kit2.5 [iU]/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Taxonomy

Classification
Not classified

Drug created on November 30, 2015 14:24 / Updated on November 02, 2018 07:03